Blog

Vendor Consolidation in Preclinical R&D: A Practical Guide

Science Exchange — Tue, 14 Jul 2026 21:46:46 GMT

Most preclinical teams did not choose to work with dozens of vendors. It happened one urgent study at a time. Consolidation is the obvious fix and the one that makes people nervous, because cutting vendors sounds like cutting the capability the science depends on. It does not have to. Done well, consolidation reduces operational drag and audit risk while keeping every capability you use. The key is consolidating the relationships and the contracting while preserving the scientific range.

What Procurement Owns When Science Is the Risk in R&D

Science Exchange — Thu, 09 Jul 2026 17:53:37 GMT

In most spend categories, a supplier is a vendor you can swap. In regulated R&D, a supplier is a source of risk that follows your molecule onto the audit record. When a contract research organization mishandles a GxP study, the finding does not stay with the vendor. It lands on the sponsor. That is the part procurement leaders in life sciences live with that their peers in other industries do not. It is why managing suppliers in regulated research is a different job than sourcing them.

The BIOSECURE Act: How It Impacts Biopharma Purchasing

Ankita Goswami, Head of Product Marketing & Sales Enablement — Wed, 08 Jul 2026 18:35:37 GMT

For years, outsourcing has been an essential part of modern drug development. Biopharma organizations rely on a global ecosystem of CROs, laboratories, manufacturers, and specialized scientific partners to accelerate research and bring therapies to patients faster.

What R&D Procurement Velocity Really Means in Life Sciences

Science Exchange — Tue, 30 Jun 2026 16:49:30 GMT

Most life sciences procurement teams measure velocity at the wrong point. They time how fast they can pick a supplier and miss the part that delays the science: everything between the decision and the started study. R&D procurement velocity is the speed from "we chose this provider" to "the work has begun," and in regulated research that distance is where weeks disappear. Closing it is the difference between a procurement function that supports the science and the intelligent infrastructure that accelerates it.

Build vs. Outsource: A Lab Startup Decision Framework

Valerie Scott, PhD, Senior Virtual Lab Manager — Thu, 25 Jun 2026 15:57:31 GMT

At some point in every lab's early life, a founder looks at the cost of outsourcing an assay for the third time and thinks: we should just bring this in-house. The math seems obvious. The capability seems within reach. The decision feels like the next logical step in building out a lab.

Why AI Pilots Stall Before Scaling in R&D Operations

Ankita Goswami, Head of Product Marketing & Sales Enablement — Wed, 24 Jun 2026 17:53:07 GMT

Across biopharma, almost everyone is using AI now: 92% of leaders report using it in at least one non-scientific use case. The pattern that tends to follow is familiar enough to be a genre. A pilot produces a promising result, leadership gets excited, and then the project quietly stalls, never quite making it into the daily work it was supposed to change.

Vendor Management vs. Supplier Orchestration in R&D

Science Exchange — Tue, 23 Jun 2026 15:56:05 GMT

Most R&D procurement teams manage dozens of external supplier relationships across disconnected systems: separate contracts, separate onboarding, separate payment entities, separate qualification records. The tools built to hold all of that are called vendor management systems. The name is accurate, and that is the limitation.

What Our Customers Taught Us About R&D Operations

Science Exchange — Thu, 18 Jun 2026 22:06:31 GMT

Nobody calls a meeting to announce they have an R&D operations problem. The realization is quieter than that. A scientist mentions, offhand, that they spent all of Tuesday chasing a supplier quote. A procurement director notices the same contract redline cycling through legal for the third time this quarter. A VP looks at the pipeline and cannot explain why a study that should have started in Q1 is still in onboarding.

Bridging the Gap: Translating Preclinical Biomarkers to Clinical Success

Crown Bioscience — Mon, 15 Jun 2026 16:44:55 GMT

Despite remarkable strides in biomarker discovery, a troubling chasm persists between preclinical promise and clinical utility. This blog explores the scientific and strategic approaches necessary to overcome translational hurdles and improve the predictive validity of preclinical biomarkers—ultimately accelerating their path to regulatory approval and patient benefit.

Lab Startup Playbook: Building Your Minimum Viable Laboratory

Elizabeth Paris, PhD, Virtual Lab Manager — Thu, 11 Jun 2026 15:26:12 GMT

There's a predictable pattern in early-stage lab setup. The equipment list starts conservatively, then grows. A second centrifuge seems prudent. A backup thermal cycler feels responsible. By the time the first order is placed, the lab is spending capital on equipment it won't need for six months. Meanwhile, the item that will actually block the first experiment is still on backorder because no one identified it as a long-lead-time item early enough.